Equazen FORTE
Natural health product licensed in Canada
- Other names
- Equazen FORTE - capsules
- Licence holder
- Soho Floridis UK Ltd.
- NPN or DIN-HM
- 80145164
- Status
- Active licence
- Licence date
- 4 November 2025
- Revision date
- Not provided
- Form
- Capsule, enrobage gélatine
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Extrait de feuilles de romarin, Alginate de sodium, Gélatine, Glycérol, Mélange de concentré de tocophérols (type alpha inférieur)
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Enfants et Adolescents | minimum: 6 years ; maximum: 18 years | 2 Capsule | 1 Tous les jours |
| Adultes | maximum: 18 years | 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps support/maintain (healthy) development of brain/(and), eyes/(and) nerves in children up to 12 years of age. Helps support/maintain brain function. Helps support/maintain cognitive health. May help reduce the symptoms associated with attention deficit hyperactivity disorder (ADHD) in school-age children.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80145164
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.